Literature DB >> 16330325

A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression.

Rui-Hong Wang1, Cuiling Li, Xiaoling Xu, Yin Zheng, Cuiying Xiao, Patricia Zerfas, Sharon Cooperman, Michael Eckhaus, Tracey Rouault, Lopa Mishra, Chu-Xia Deng.   

Abstract

Hereditary hemochromatosis, characterized by iron overload in multiple organs, is one of the most common genetic disorders among Caucasians. Hepcidin, which is synthesized in the liver, plays important roles in iron overload syndromes. Here, we show that a Cre-loxP-mediated liver-specific disruption of SMAD4 results in markedly decreased hepcidin expression and accumulation of iron in many organs, which is most pronounced in liver, kidney, and pancreas. Transcript levels of genes involved in intestinal iron absorption, including Dcytb, DMT1, and ferroportin, are significantly elevated in the absence of hepcidin. We demonstrate that ectopic overexpression of SMAD4 activates the hepcidin promoter and is associated with epigenetic modification of histone H3 to a transcriptionally active form. Moreover, transcriptional activation of hepcidin is abrogated in SMAD4-deficient hepatocytes in response to iron overload, TGF-beta, BMP, or IL-6. Our study uncovers a novel role of TGF-beta/SMAD4 in regulating hepcidin expression and thus intestinal iron transport and iron homeostasis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16330325     DOI: 10.1016/j.cmet.2005.10.010

Source DB:  PubMed          Journal:  Cell Metab        ISSN: 1550-4131            Impact factor:   27.287


  254 in total

1.  Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease.

Authors:  James E Nelson; Laura Wilson; Elizabeth M Brunt; Matthew M Yeh; David E Kleiner; Aynur Unalp-Arida; Kris V Kowdley
Journal:  Hepatology       Date:  2010-11-29       Impact factor: 17.425

2.  A tincture of hepcidin cures all: the potential for hepcidin therapeutics.

Authors:  Thomas B Bartnikas; Mark D Fleming
Journal:  J Clin Invest       Date:  2010-11-22       Impact factor: 14.808

Review 3.  Unraveling mechanisms regulating systemic iron homeostasis.

Authors:  Karin E Finberg
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

Review 4.  Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation.

Authors:  Chia Chi Sun; Valentina Vaja; Jodie L Babitt; Herbert Y Lin
Journal:  Am J Hematol       Date:  2012-01-31       Impact factor: 10.047

Review 5.  Iron homeostasis and the inflammatory response.

Authors:  Marianne Wessling-Resnick
Journal:  Annu Rev Nutr       Date:  2010-08-21       Impact factor: 11.848

Review 6.  Hepcidin and iron homeostasis.

Authors:  Tomas Ganz; Elizabeta Nemeth
Journal:  Biochim Biophys Acta       Date:  2012-01-26

Review 7.  Anemia, ineffective erythropoiesis, and hepcidin: interacting factors in abnormal iron metabolism leading to iron overload in β-thalassemia.

Authors:  Sara Gardenghi; Robert W Grady; Stefano Rivella
Journal:  Hematol Oncol Clin North Am       Date:  2010-10-15       Impact factor: 3.722

8.  Smad1/5 is required for erythropoietin-mediated suppression of hepcidin in mice.

Authors:  Chia-Yu Wang; Amanda B Core; Susanna Canali; Kimberly B Zumbrennen-Bullough; Sinan Ozer; Lieve Umans; An Zwijsen; Jodie L Babitt
Journal:  Blood       Date:  2017-04-24       Impact factor: 22.113

Review 9.  The pathophysiology and pharmacology of hepcidin.

Authors:  Piotr Ruchala; Elizabeta Nemeth
Journal:  Trends Pharmacol Sci       Date:  2014-02-17       Impact factor: 14.819

Review 10.  A systems biology approach to iron metabolism.

Authors:  Julia Chifman; Reinhard Laubenbacher; Suzy V Torti
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.